ProCE Banner Activity

Phase II DREAMM-2 Study of Belantamab Mafodotin in R/R MM: Outcomes by Number of Prior Therapies

Slideset Download
Conference Coverage
One-year outcomes from the phase II DREAMM-2 trial showed comparable outcomes with belantamab mafodotin in patients with R/R MM after either 3-6 or ≥ 7 prior lines of therapy.

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology